Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 3/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.59 |
| ▸ | JAK2 | O60674 | 11/20 | 0.40 |
| ▸ | JAK3 | P52333 | 5/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3754658 | 0.75 | MAPK8 (0.81) | MAPK10MAPK8JAK2JAK3CDK2 | |
| SCHEMBL3759154 | 0.73 | MAPK10 (0.78) | MAPK10MAPK8JAK2JAK3IKBKB | |
| SCHEMBL3756383 | 0.72 | MAPK8 (0.69) | MAPK10MAPK8JAK2CDK2AURKA | |
| SCHEMBL3758774 | 0.69 | MAPK10 (0.71) | MAPK10MAPK8JAK2JAK3HDAC1 | |
| SCHEMBL14045293 | 0.67 | MAPK8 (0.48) | MAPK10MAPK8JAK2JAK3CDK2 | |
| SCHEMBL3753808 | 0.67 | MAPK10 (0.70) | MAPK10MAPK8JAK2JAK3 | |
| SCHEMBL13588445 | 0.67 | MAPK8 (0.82) | MAPK10MAPK8JAK2JAK3HDAC1 | |
| SCHEMBL3755971 | 0.66 | MAPK10 (0.68) | MAPK10MAPK8JAK2JAK3 | |
| SCHEMBL3753229 | 0.66 | CLK1 (0.69) | MAPK10MAPK8JAK2CDK2 | |
| SCHEMBL3759150 | 0.65 | MAPK10 (0.65) | MAPK10MAPK8JAK2JAK3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200436-B1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | SCRIPPS RESEARCH INST (US) | 2015-01-21 | — | — | EP | disclosed |
| US-20150004231-A1 | FORMULATIONS AND PHARMACOKINETICS OF DEUTERATED BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | AUSPEX PHARMACEUTICALS LLC | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150004231-A1 | FORMULATIONS AND PHARMACOKINETICS OF DEUTERATED BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | SLC18A2, SLC6A2, SLC18A1 | MAPK10 3557/4885MAPK8 4132/4885JAK2 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.